Stock listing
Frankfurt:IF0 InflaRx N.V. Aktie
German listing (Frankfurt) of InflaRx N.V. · home listing NASDAQ:IFRX
Follow InflaRx N.V. into a list and get an email when it puts out news.
Share price · FWB:IF0
€0.949 EUR +0.001 (+0.1%)
Close on Nov 20, 2026
- Day range
- €0.937 – €0.949 EURNov 20, 2026
- Volume
- 1,500 sharesNov 20, 2026
- Market cap
- €139.9M EURAt the close on Nov 20, 2026 · price × 147.4M shares outstanding
- 52-week range
- €0.661 – €2.439 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €14,442 EURMedian day 600 shares · 24 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:IFRX · Home | $1.04 USD | -0.07 (-6.3%) | 472,105 | $1.06 | $1.116 | $1.03 | $1.11 | Close on Nov 20, 2026 |
| Frankfurt:IF0 | €0.949 EUR | +0.001 (+0.1%) | 1,500 | €0.937 | €0.949 | €0.937 | €0.948 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:IF0 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €1.061 | -0.186 | -14.9% | €1.175 | €1.182 | €1.057 | 1,000 | |
| €1.247 | -0.080 | -6.0% | €1.287 | €1.287 | €1.238 | 40,000 | |
| €1.327 | -0.158 | -10.6% | €1.398 | €1.412 | €1.326 | 243,102 | |
| €1.485 | +0.031 | +2.1% | €1.516 | €1.516 | €1.326 | 0 | |
| €1.454 | +0.047 | +3.3% | €1.455 | €1.455 | €1.448 | 0 | |
| €1.407 | -0.102 | -6.8% | €1.488 | €1.491 | €1.405 | 800 | |
| €1.509 | +0.070 | +4.9% | €1.517 | €1.538 | €1.495 | 6,838 | |
| €1.439 | +0.045 | +3.2% | €1.473 | €1.482 | €1.429 | 8,216 | |
| €1.394 | +0.009 | +0.6% | €1.397 | €1.397 | €1.392 | 600 | |
| €1.385 | +0.098 | +7.6% | €1.385 | €1.385 | €1.385 | 26,710 | |
| €1.287 | -0.083 | -6.1% | €1.386 | €1.389 | €1.276 | 20,638 | |
| €1.370 | -0.002 | -0.1% | €1.354 | €1.379 | €1.331 | 0 | |
| €1.372 | -0.025 | -1.8% | €1.372 | €1.372 | €1.372 | 8,300 | |
| €1.397 | +0.281 | +25.2% | €1.263 | €1.404 | €1.233 | 30,900 | |
| €1.116 | -0.076 | -6.4% | €1.189 | €1.190 | €1.105 | 2,665 | |
| €1.192 | -0.056 | -4.5% | €1.262 | €1.265 | €1.189 | 0 | |
| €1.248 | -0.071 | -5.4% | €1.248 | €1.248 | €1.248 | 0 | |
| €1.319 | -0.075 | -5.4% | €1.347 | €1.353 | €1.297 | 10,060 | |
| €1.394 | +0.059 | +4.4% | €1.356 | €1.403 | €1.349 | 9,900 | |
| €1.335 | -0.008 | -0.6% | €1.428 | €1.433 | €1.331 | 0 | |
| €1.343 | +0.045 | +3.5% | €1.345 | €1.358 | €1.343 | 30,220 | |
| €1.298 | -0.056 | -4.1% | €1.380 | €1.398 | €1.295 | 22,974 | |
| €1.354 | -0.053 | -3.8% | €1.349 | €1.357 | €1.336 | 0 | |
| €1.407 | -0.049 | -3.4% | €1.483 | €1.484 | €1.405 | 3,000 | |
| €1.456 | -0.018 | -1.2% | €1.489 | €1.492 | €1.446 | 10,000 | |
| €1.474 | -0.047 | -3.1% | €1.524 | €1.529 | €1.472 | 11,482 | |
| €1.521 | -0.030 | -1.9% | €1.574 | €1.603 | €1.519 | 0 | |
| €1.551 | +0.024 | +1.6% | €1.625 | €1.625 | €1.535 | 0 | |
| €1.527 | -0.032 | -2.1% | €1.550 | €1.552 | €1.516 | 0 | |
| €1.559 | -0.117 | -7.0% | €1.577 | €1.580 | €1.554 | 0 | |
| €1.676 | +0.040 | +2.4% | €1.676 | €1.676 | €1.676 | 2,984 | |
| €1.636 | -0.131 | -7.4% | €1.636 | €1.636 | €1.636 | 1,000 | |
| €1.767 | -0.025 | -1.4% | €1.774 | €1.791 | €1.767 | 1,000 | |
| €1.792 | +0.002 | +0.1% | €1.792 | €1.792 | €1.792 | 0 | |
| €1.790 | +0.081 | +4.7% | €1.790 | €1.790 | €1.790 | 0 | |
| €1.709 | +0.019 | +1.1% | €1.737 | €1.752 | €1.686 | 4,600 | |
| €1.690 | +0.032 | +1.9% | €1.747 | €1.753 | €1.689 | 500 | |
| €1.658 | -0.085 | -4.9% | €1.731 | €1.732 | €1.654 | 0 | |
| €1.743 | -0.039 | -2.2% | €1.800 | €1.805 | €1.723 | 0 | |
| €1.782 | +0.076 | +4.5% | €1.758 | €1.794 | €1.718 | 400 | |
| €1.706 | +0.033 | +2.0% | €1.729 | €1.730 | €1.705 | 4,000 | |
| €1.673 | -0.061 | -3.5% | €1.730 | €1.736 | €1.671 | 0 | |
| €1.734 | -0.060 | -3.3% | €1.809 | €1.821 | €1.725 | 0 | |
| €1.794 | -0.089 | -4.7% | €1.890 | €1.892 | €1.766 | 0 | |
| €1.883 | +0.061 | +3.3% | €1.883 | €1.883 | €1.883 | 0 | |
| €1.822 | -0.017 | -0.9% | €1.872 | €1.881 | €1.807 | 55,036 | |
| €1.839 | -0.027 | -1.4% | €1.984 | €1.993 | €1.818 | 0 | |
| €1.866 | +0.150 | +8.7% | €1.819 | €1.873 | €1.805 | 1,700 | |
| €1.716 | -0.118 | -6.4% | €1.773 | €1.777 | €1.706 | 0 | |
| €1.834 | -0.026 | -1.4% | €1.884 | €1.884 | €1.833 | 400 | |
| €1.860 | -0.058 | -3.0% | €1.907 | €1.918 | €1.852 | 11,568 | |
| €1.918 | -0.153 | -7.4% | €2.020 | €2.029 | €1.913 | 0 | |
| €2.071 | +0.398 | +23.8% | €1.989 | €2.076 | €1.960 | 5,500 | |
| €1.673 | -0.023 | -1.4% | €1.702 | €1.720 | €1.670 | 0 | |
| €1.696 | +0.022 | +1.3% | €1.736 | €1.736 | €1.691 | 0 | |
| €1.674 | -0.053 | -3.1% | €1.695 | €1.702 | €1.668 | 5,558 | |
| €1.727 | -0.093 | -5.1% | €1.735 | €1.735 | €1.712 | 150 |
- Ticker
- Frankfurt:IF0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 6, 2026
InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan
Latest deck · Nov 3, 2026
Investor Day (November 2026)
Investor day · 77 slides
Latest news
InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan
Nov 6, 2026
Closed €1.06 (-14.9%) on Nov 6, 2026
InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day
Nov 3, 2026
Closed €1.49 (+2.1%) on Nov 3, 2026
InflaRx Announces November Investor Events
Oct 27, 2026
Closed €1.39 (+0.6%) on Oct 27, 2026
InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
Oct 22, 2026
Closed €1.29 (-6.1%) on Oct 23, 2026
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
Oct 2, 2026
Closed €1.47 (-3.1%) on Oct 2, 2026
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President and Global Head of Clinical Development
Oct 2, 2026
Closed €1.47 (-3.1%) on Oct 2, 2026
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
Oct 1, 2026
Closed €1.52 (-1.9%) on Oct 1, 2026
InflaRx to Host Virtual Capital Markets Day
Sep 21, 2026
Closed €1.79 (+4.7%) on Sep 21, 2026
InflaRx Announces Participation in September Investor Conferences
Aug 20, 2026
Closed €1.73 (-5.1%) on Aug 20, 2026
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
Aug 6, 2026
Closed €1.54 (+2.3%) on Aug 6, 2026
InflaRx N.V. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 27 in the last 12 months · 118 in all · newest Nov 6, 2026 · oldest 2020
- Decks
- 37 decks · latest Nov 3, 2026
Where InflaRx N.V. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:IFRX · Home listing | NASDAQ | United States | USD |
| Tradegate:IF0 | Tradegate | Germany | EUR |
| gettex:IF0 | gettex | Germany | EUR |
| LS Exchange:A2H7A5 | LS Exchange | Germany | EUR |
| Frankfurt:IF0 · This page | Frankfurt | Germany | EUR |
| Lang & Schwarz:A2H7A5 | Lang & Schwarz | Germany | EUR |
| Stuttgart:IF0 | Stuttgart | Germany | EUR |
| BOATS:IFRX | BOATS | United States | USD |
| BMV:IFRXN | BMV | Mexico | MXN |
| Munich:IF0 | Munich | Germany | EUR |
| BIVA:IFRXN | BIVA | Mexico | MXN |
| Dusseldorf:IF0 | Dusseldorf | Germany | EUR |
| Hamburg:IF0 | Hamburg | Germany | EUR |
Valuation
EV/sales 4,215× against a median of 74.5×: 8th lowest of 9 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · price Nov 20, 2026
- Enterprise value
- $135.7M USD
- P/E
- Loss
- EV/sales
- 4,215×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 19.5×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.61
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| InflaRx N.V. · NASDAQ:IFRX | US$153.3M | US$135.7M | n/a | 4,215× | n/a | 19.5× | n/a | 0.0× | 1.61 |
| ImmuneOncia Therapeutics Inc. · KRX:424870 | US$160.0M | US$90.35M | n/a | n/a | n/a | 2.1× | n/a | 0.0× | n/a |
| Baijin Life Science Holdings Limited · HKEX:1466 | US$160.0M | US$158.1M | n/a | 13.9× | n/a | 6.8× | −42.4% | 0.1× | n/a |
| Jiangsu Recbio Technology Co., Ltd. Class H · HKEX:2179 | US$157.3M | US$230.0M | n/a | 124× | n/a | 2.1× | n/a | 1.4× | n/a |
| BioVersys AG · SIX:BIOV | US$154.1M | US$97.45M | n/a | 102× | n/a | 2.9× | n/a | 0.5× | n/a |
| Polaris Group · TWSE:6550 | US$153.0M | US$154.8M | n/a | 75.1× | n/a | 1.1× | n/a | 0.5× | n/a |
| ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H · HKEX:1541 | US$152.0M | US$64.59M | n/a | 2.9× | n/a | 1.6× | −141.7% | 0.6× | n/a |
| Saniona AB · OMXSTO:SANION | US$151.6M | US$104.0M | 8.4× | 2.5× | 5.2× | 2.8× | 43.2% | 0.0× | n/a |
| Palisade Bio, Inc. · NASDAQ:PALI | US$150.6M | US$36.96M | n/a | 73.9× | n/a | 1.3× | n/a | 0.0× | 1.41 |
| Eledon Pharmaceuticals, Inc. · NASDAQ:ELDN | US$150.3M | US$80.67M | n/a | n/a | n/a | 4.9× | n/a | 0.0× | 1.95 |
| Veraxa Biotech AG · NASDAQ:VRXA | US$147.1M | US$145.1M | n/a | 5,202× | n/a | n/a | n/a | n/a | 1.11 |
| Median of the others | US$152.5M | US$100.7M | 8.4× | 74.5× | 5.2× | 2.1× | −42.4% | 0.1× | 1.41 |
Forecasts
7 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.
- Price target
- 8.27 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.20 · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Niels C. Riedemann | Chief Executive Officer and Founder |
| Thomas Taapken | Chief Financial Officer |
| Christian Schmid | VP, Head of Legal Affairs & General Counsel |
| Jan Medina | Vice President, Head of Investor Relations |
| Derval O’Carroll | Senior Vice President, Global Head of Regulatory Affairs & Compliance |
| Gabriela Alperovich | Senior Vice President & Global Head of Clinical Development |
| Kofi Boaten | VP, Head of Supply Quality & Clinical Trial Supplies |
| Maria Habel | VP, Head of preclinical R&D and QC |
| Petra Eßer | VP, Head of Finance and Controlling |
| Daniel Vetter | Senior Director, Head of IT |
| Igor Orshanskiy | Senior Director, Head of Business Development |
| Kirsten Cremering | Senior Director, Head of Quality Assurance |
| Peter Hurt | Senior Director, Head of Drug Safety and Pharmacovigilance |
| Renfeng Guo | Chief Scientific Officer and Founder |
| Tony Gibney | Board Member, Head of Audit Committee |
Board
| Director | Role |
|---|---|
| Nicolas Fulpius | Chairman of the Board |
| Andreas Kronbichler | |
| David Jayne | Board Member |
| Hege Hellstrom | Board Member |
| Jonathan Barratt | Board Member |
| Jürgen Floege | Board Member |
| Mark Kubler | Board Member |
| med. Bernhard Hellmich | Board Member |
| Ming-hui ZHAO | |
| Peter A. Merkel | Board Member |
| Richard Brudnick | Board Member |
| Tony Gibney | Board Member, Head of Audit Committee |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 3, 2026 · Before open | −8.2% |
| Quarter to Jun 30, 2026 | Aug 6, 2026 · Before open | −2.8% |
| Quarter to Mar 31, 2026 | May 13, 2026 | −2.1% |
| Quarter to Dec 31, 2025 | Mar 19, 2026 · Before open | +3.4% |
| Quarter to Sep 30, 2025 | Nov 10, 2025 · Before open | +28.5% |
| Q2 2025 | Aug 7, 2025 · Before open | −3.0% |
| Quarter to Mar 31, 2025 | May 7, 2025 · Before open | −7.5% |
| Quarter to Dec 31, 2024 | Mar 20, 2025 | 0.0% |
| Quarter to Sep 30, 2024 | Nov 8, 2024 · Before open | +3.3% |
| Q2 2024 | Aug 8, 2024 · Before open | −5.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2024 | May 8, 2024 · Before open | −3.2% |
| Quarter to Dec 31, 2023 | Mar 21, 2024 · Before open | −8.9% |
| Quarter to Sep 30, 2023 | Nov 1, 2023 · Before open | −4.1% |
| Q2 2023 | Aug 10, 2023 · Before open | +9.6% |
| Quarter to Mar 31, 2023 | May 11, 2023 · Before open | +7.5% |
| Quarter to Dec 31, 2022 | Mar 22, 2023 · Before open | +10.7% |
| Quarter to Sep 30, 2022 | Nov 9, 2022 · Before open | −1.8% |
| Q2 2022 | Aug 5, 2022 · Before open | −5.2% |
| Quarter to Mar 31, 2022 | May 12, 2022 · Before open | +6.6% |
| Quarter to Dec 31, 2021 | Mar 24, 2022 · Before open | +5.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Day (November 2026) | Investor day | 77 slides | Nov 3, 2026 |
| Investor Day (November 2026) | Investor day | 76 slides | Nov 3, 2026 |
| Investor Presentation (August 2026) | Investor deck | 37 slides | August 2026 |
| Investor Presentation (May 2026) | Investor deck | 38 slides | May 6, 2026 |
| Investor Presentation (May 2026) | Investor deck | 38 slides | May 2026 |
| Investor Presentation (April 2026) | Investor deck | 67 slides | Apr 9, 2026 |
| Investor Presentation (February 2026) | Investor deck | 67 slides | Feb 25, 2026 |
| Technical Presentation (November 2025) | Technical | 43 slides | Nov 10, 2025 |
| Investor Presentation (August 2025) | Investor deck | 49 slides | August 2025 |
| Investor Presentation (May 2025) | Investor deck | 55 slides | May 2025 |
All 37 decks
Financings
| Raise | Date |
|---|---|
| Public offering of ordinary shares and pre-funded warrants Closed: US$30M raised · US$2 a share · Warrants at US$0.001 · Guggenheim Securities, LLC +2 Dealers: Guggenheim Securities, LLC (lead), H.C. Wainwright & Co. (co-lead), Lucid Capital Markets, LLC (co-lead) Use of proceeds: Clinical development of pipeline candidates including vilobelimab and INF904, and general corporate purposes | Feb 18, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Fireman B.V. Priced at US$15.00 a share on Nov 7, 2017.
- Price
- US$15.00 a share
- Shares offered
- 6,667,000 common shares
- Offering size
- US$100 million
- Underwriters' option
- Up to 1,000,050 more shares
- Underwriters
- J.P. Morgan, Leerink Partners, BMO Capital Markets · In the order on the cover
- Shares delivered
- On or about Nov 10, 2017
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jun 23, 2017 |
| Filed publicly | Oct 13, 2017 |
| Amended 4 times | Newest Nov 7, 2017 |
| Shares registered with an exchange | Nov 7, 2017 |
| Declared effective by the SEC | Nov 7, 2017 |
| Final prospectus, with the price | Nov 8, 2017 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Nov 8, 2017 |
| CERTNAS · Nasdaq's certificate of listing | Nov 7, 2017 |
| EFFECT · Notice that a registration is effective | Nov 7, 2017 |
| 8-A12B · Registration of shares for listing on an exchange | Nov 7, 2017 |
| F-1/A · Registration statement, amended | Nov 7, 2017 |
| CORRESP · Letter to the SEC | Nov 3, 2017 |
| CORRESP · Letter to the SEC | Nov 3, 2017 |
| F-1/A · Registration statement, amended | Oct 31, 2017 |
| CORRESP · Letter to the SEC | Oct 31, 2017 |
| UPLOAD · Letter from the SEC | Oct 31, 2017 |
All 27 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Oct 30, 2017 |
| F-1/A · Registration statement, amended | Oct 30, 2017 |
| UPLOAD · Letter from the SEC | Oct 27, 2017 |
| F-1/A · Registration statement, amended | Oct 26, 2017 |
| CORRESP · Letter to the SEC | Oct 26, 2017 |
| UPLOAD · Letter from the SEC | Oct 25, 2017 |
| CORRESP · Letter to the SEC | Oct 18, 2017 |
| F-1 · Registration statement | Oct 13, 2017 |
| CORRESP · Letter to the SEC | Oct 13, 2017 |
| UPLOAD · Letter from the SEC | Sep 21, 2017 |
| DRSLTR · Letter to the SEC with a draft | Sep 11, 2017 |
| DRS/A · Draft registration statement, amended | Sep 11, 2017 |
| UPLOAD · Letter from the SEC | Aug 16, 2017 |
| DRSLTR · Letter to the SEC with a draft | Aug 3, 2017 |
| DRS/A · Draft registration statement, amended | Aug 3, 2017 |
| UPLOAD · Letter from the SEC | Jul 21, 2017 |
| DRS · Draft registration statement | Jun 23, 2017 |
Open IPO · From the cover of the final prospectus (424B4) filed Nov 8, 2017
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 29.3K | 165.8K | 63.1K | |||||||
| Cost of revenue | 7.27M | 3.32M | 532.3K | |||||||
| Gross profit | -7.24M | -3.15M | -469.2K | -37.8M | -19.6M | -7.12M | ||||
| Research and development | 25.7M | 35.4M | 41.0M | 37.5M | 35.7M | 25.7M | 44.6M | 25.0M | 14.4M | 5.28M |
| Selling, general and administrative | 16.0K | 41.4K | 95.2K | 97.4K | 105.8K | 8.47M | 12.5M | 12.8M | 5.14M | 1.84M |
| Operating income | -44.9M | -32.2M | -47.6M | |||||||
| Depreciation and amortization | 419.5K | 485.1K | 567.8K | 596.6K | 669.4K | 712.7K | 663.2K | 173.6K | 70.9K | 33.0K |
| EBITDA | -44.3M | -31.6M | -47.0M | |||||||
| Interest expense | 2.69K | 885 | 16.5K | 23.3K | 10.7K | 18.7K | 0 | 0 | 4.92M | 2.05M |
| Income before tax | -45.6M | -46.1M | -42.7M | -29.5M | -45.6M | -34.0M | -53.3M | -29.8M | -24.2M | -8.94M |
| Income tax | 12.3K | 5.22K | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Net income | -45.6M | -46.1M | -42.7M | -29.5M | -45.6M | -34.0M | -53.3M | -29.8M | -24.2M | -8.94M |
| Earnings per share, basic | -0.68 | -0.78 | -0.78 | -0.67 | -1.10 | -1.26 | ||||
| Earnings per share, diluted | -0.68 | -0.78 | -0.78 | -0.67 | -1.10 | -1.26 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 16.0M | 18.4M | 12.8M | 16.3M | 26.2M | 26.0M | 33.1M | 55.4M | 123.3M | 29.1M |
| Inventory | 6.90M | 11.4M | ||||||||
| Current assets | 53.6M | 71.7M | 109.5M | 97.4M | 95.7M | 86.3M | 119.0M | 158.2M | 124.0M | 29.4M |
| Property, plant and equipment | 289.3K | 256.3K | 289.6K | 328.9K | 274.4K | 408.3K | 576.4K | 624.7K | 173.0K | |
| Total assets | 55.2M | 76.0M | 120.2M | 102.4M | 125.1M | 88.2M | 121.6M | 159.2M | 124.2M | 29.5M |
| Accounts payable | 5.40M | 11.4M | 12.0M | 4.99M | 8.57M | 8.26M | 12.4M | 6.66M | 4.47M | 1.53M |
| Current liabilities | 13.0M | 14.2M | 16.8M | 13.0M | 18.8M | 10.1M | 14.1M | 7.76M | 4.77M | 1.75M |
| Long-term debt | 0 | |||||||||
| Total debt | 0 | |||||||||
| Total liabilities | 13.7M | 14.6M | 17.6M | 14.1M | 19.9M | 10.4M | 14.4M | 7.82M | 4.78M | |
| Shareholders' equity | 7.17M | 7.44M | 7.38M | 7.26M | 105.3M | 77.9M | 107.1M | 151.4M | 119.4M | -25.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -35.3M | -48.6M | -37.8M | -33.7M | -39.9M | -36.5M | -43.2M | -21.5M | -12.2M | -4.99M |
| Cash from investing | 3.23M | 52.4M | -17.7M | 19.4M | -26.0M | 21.4M | 20.3M | -99.4M | -167.0K | -53.0K |
| Cash from financing | 33.3M | 386.4K | 53.0M | 1.94M | 61.6M | 9.17M | -294.3K | 49.6M | 108.8M | 30.9M |
| Change in cash | 1.24M | 4.19M | -2.52M | -12.4M | -4.31M | -5.99M | -23.2M | -71.4M | 94.2M | 25.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 6, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 3, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 3, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 22, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 424B5 · Prospectus | Aug 14, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
Show 200 filings
This page holds 200 of 291 filings. Open Filings
Cap table
Built by 6ix from InflaRx N.V.’s releases · as of Feb 18, 2025
- Common shares
- 147,368,221
- Fully diluted
- 147,368,221
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 147,368,221 |
Warrants and options
| Lot |
|---|
| Warrants · US$0.001 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 147,368,221 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Richard Brudnick Other companies: Scholar Rock Holding Corporation (Director · Since at least Apr 6, 2023); Prime Medicine, Inc. (Chief Business Officer · Oct 19, 2022 – May 20, 2025 · Past); VolitionRx Limited (Director · Mar 25, 2021 – Jan 12, 2023 · Past); Codiak BioSciences Inc (See Remarks · Oct 13, 2020 – Feb 16, 2022 · Past); Bioverativ Inc (EVP, Business Development · Dec 22, 2016 – Mar 8, 2018 · Past) | Board Member · Since at least Mar 18, 2026 |
| Anthony S Gibney Other companies: Aura Biosciences, Inc. (See Remarks · Since at least May 13, 2025) | Director · Since at least Mar 18, 2026 |
| Andreas Kronbichler | Director · Since at least Nov 3, 2026 |
| Christian Schmid | VP, Head of Legal Affairs & General Counsel · Since at least Nov 5, 2026 |
| Daniel Vetter | Senior Director, Head of IT · Since at least Nov 5, 2026 |
| David Jayne | Board Member · Since at least Nov 3, 2026 |
| Derval O’Carroll | Senior Vice President, Global Head of Regulatory Affairs & Compliance · Since at least Mar 18, 2026 |
| Gabriela Alperovich | Senior Vice President & Global Head of Clinical Development · Since Oct 1, 2026 |
| Hege Hellstrom | Board Member · Since at least Nov 5, 2026 |
| Igor Orshanskiy | Senior Director, Head of Business Development · Since at least Nov 5, 2026 |
All 27 people
| Person | Seat |
|---|---|
| Jan Medina | Vice President, Head of Investor Relations · Since at least Nov 3, 2026 |
| Jonathan Barratt | Board Member · Since at least Nov 3, 2026 |
| Jürgen Floege | Board Member · Since at least Nov 3, 2026 |
| Kirsten Cremering | Senior Director, Head of Quality Assurance · Since at least Nov 5, 2026 |
| Kofi Boaten | VP, Head of Supply Quality & Clinical Trial Supplies · Since at least Nov 5, 2026 |
| Maria Habel | VP, Head of preclinical R&D and QC · Since at least Nov 5, 2026 |
| Mark Kubler | Director · Since at least Mar 18, 2026 |
| med. Bernhard Hellmich | Board Member · Since at least Nov 3, 2026 |
| Ming-hui ZHAO | Director · Since at least Nov 3, 2026 |
| Nicolas Fulpius | Chairman of the Board · Since at least Mar 18, 2026 |
| Niels C. Riedemann | Chief Executive Officer, Director · Since at least Mar 18, 2026 |
| Peter A. Merkel | Board Member · Since at least Nov 3, 2026 |
| Peter Hurt | Senior Director, Head of Drug Safety and Pharmacovigilance · Since at least Nov 5, 2026 |
| Petra Eßer | VP, Head of Finance and Controlling · Since at least Nov 5, 2026 |
| Renfeng Guo | Chief Scientific Officer, Director · Since at least Mar 18, 2026 |
| Thomas Taapken | Chief Financial Officer · Since at least Aug 6, 2026 |
| Tony Gibney | Board Member, Head of Audit Committee · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about InflaRx N.V.